Trelagliptin Succinate

琥珀酸曲格列汀

Report date: 2024/03/20 11:42:05
NME

Base Information

Drug NameTrelagliptin Succinate
Drug Alias Nametrelagliptinum琥珀酸曲格列汀trelagliptina琥珀酸曲拉格列汀SYR-472 succinate +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryJapan
Original Approved Date2015/03/26
Country/TerritoryCzechiaUnited StatesUkraine +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKhyber Medical College PeshawarTeijin Pharma LtdTakeda Pharmaceutical Co Ltd +[4] 
Inactive CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co LtdNanjing Wanchuan Medicine Technology Development Co Ltd +[5] 
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10BH
Related LinksWikipediaKEGG